U.S. FDA Approves Tremfya For The Treatment Of Pediatric Plaque

ReutersSep 29, 2025 12:33 PM

View all comments（0）



Sept 29 (Reuters) - Johnson & Johnson JNJ.N:

U.S. FDA APPROVES TREMFYA® (GUSELKUMAB) FOR THE TREATMENT OF PEDIATRIC PLAQUE PSORIASIS AND ACTIVE PSORIATIC ARTHRITIS, MARKING A FIRST AND ONLY APPROVAL FOR AN IL-23 INHIBITOR

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Comments (0)

Click the $ button, enter the symbol, and select to link a stock, ETF, or other ticker.

Commenting Guidelines

Recommended Articles

Will Nvidia Stock Pop on May 20 Earnings? How to Position Now

TradingKey - The results for Nvidia (NVDA) will be announced on May 20 after the market closes, and this report is very important for more than just one stock symbol.

Samsung’s Largest Strike in History: Can SK Hynix and Micron Sit Back and Reap the Benefits?

TradingKey - On May 21, 61,000 union members at Samsung Electronics will launch an 18-day general strike, following a 93.1% approval vote. Government mediation between labor and management has collapsed.

Japan and South Korea Stocks Open Lower, Samsung Strike Storm and Higher-Than-Expected Inflation Disrupt Markets

TradingKey - On May 13, the Nikkei 225 Index opened 0.5% lower, while South Korea’s KOSPI Index opened down 1.7% before losses further widened to 3%.

Cerebras Systems IPO 2026: Date, Price, Valuation, and Whether CBRS Is Worth Buying

TradingKey - Cerebras Systems (CBRS) IPO prices May 13–14 at $125–$135/share. $26–$27B valuation, 20x oversubscribed, $510M revenue, 47% net margin, OpenAI 750MW deal. Everything you need to know.

SK Hynix Surges 15% to New High: HBM Shortage Until 2028, How Much Longer Can AI Memory King Rise?

TradingKey - During the Asian trading session on May 11, SK Hynix shares rose by more than 15% at one point, hitting an all-time intraday high of 1.949 million KRW, with its market capitalization surpassing $900 billion. The year-to-date cumulative gain is approximately 197.03%, with the share price nearly tripling.

Featured Tools